BioSpace News Archive

West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, announced the Company’s Board of Directors has elected Stephen Lockhart, M.D., Ph.D., as its newest member.

Editas Medicine, Inc., a leading genome editing company, announced the dosing and confirmed successful neutrophil and platelet engraftment of the first patient in the Phase 1/2 RUBY trial of EDIT-301 for the treatment of severe sickle cell disease.

MediciNova, Inc. announced that it has received a Notice of Allowance from the Korean Intellectual Property Office for a pending patent application which covers MN-001 and MN-002 for the treatment of fibrosis which includes a wide range of fibrotic diseases.

Integra LifeSciences Holdings Corporation, a leading global medical technology company, reported financial results for the second quarter ending June 30, 2022.

Quest Diagnostics, the world’s leading provider of diagnostic information services, announced it has been named to the 2022 Disability Equality Index® Best Places to Work for Disability Inclusion by Disability: IN and the American Association of People with Disabilities.

BD, a leading global medical technology company, and CerTest Biotec announced their newly developed molecular polymerase chain reaction test for the monkeypox virus is now commercially available outside of the United States for use in research applications by laboratories.

Alkermes plc (Nasdaq: ALKS) today reported financial results for the second quarter of 2022 and provided updated financial expectations for full-year 2022.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage, clinical biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces the appointment of Mayo Pujols as Chief Technical Officer (CTO) and Executive Vice President.

AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage allogeneic T-cell immunotherapy company, today announced that it has entered into a securities purchase agreement with a group of institutional and strategic investors to sell 27,458,095 shares of common stock.

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that Dr. William G. Rice, Chairman, President and CEO of Aptose, and Mr. Fletcher Payne, CFO of Aptose, will attend the Canaccord Genuity 42nd Annual Growth Conference.